ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nilotinib has a number of other kinase targets in addition to BCR::ABL1, including Abelson 1, KIT and platelet derived growth factor receptor [42], which results in apoptosis of healthy cells as well as BP-CML cells, although to a lesser degree.